Israel’s Biond Biologics (reported here previously) has signed an exclusive worldwide license agreement with Sanofi for its innovative cancer therapies. Biond will receive $125 million up-front with more than $1 billion in potential payments. Biond’s plans BND-22 human trials to start mid-2021.

https://jewishbusinessnews.com/2021/01/12/biond-biologics-and-sanofi-enter-into-global-licensing-agreement-worth-1-billion/